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Abstract. 
In this study the synthesis and characterization of a new dual, imaging and therapeutic, agent is 
proposed with the aim of improving the efficacy of Boron Neutron Capture Therapy (BNCT) in 
cancer treatment. The agent (Gd-B-AC01) consists of a carborane unit (ten boron atoms) bearing a 
cholesterol unit on one side (to pursue the incorporation into the liposome bi-layer), and a 
Gd(III)/1,4,7,10-tetraazacyclododecane monoamide complex on the other side (as MRI reporter to 
attain the quantification of B/Gd concentration). In order to endow the BNCT agent with specific 
delivery properties, the liposome embedded with the MRI/BNCT dual probes has been 
functionalized with a peghilated phospholipid containing a folic acid residue at the end of the PEG 
chain. The vector allows the binding of the liposome to folate receptors that are overexpressed in 
many tumors types, and in particular, in human ovarian cancer cells (IGROV-1). In vitro test on 
IGROV-1 cells demonstrated that Gd-B-AC01 loaded liposomes are efficient carriers for the 
delivery of the MRI/BNCT probes to the tumor cells.  Finally, the BNCT treatment of IGROV-1 
cells showed that the number of survived cells was markedly smaller when the cells were irradiated 
after internalization of the folate-targeted GdB10-AC01/liposomes. 
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Introduction 
Boron Neutron Capture Therapy (BNCT) is a binary treatment that combines low energy 
neutron irradiation with the presence of boron-containing compounds at the target cells. This 
methodology has been proposed for several pathologies, although most of the efforts have been 
focused on cancer.
1-3
 BNCT has been under investigation for many years, but it has not entered  
routine clinical practice yet. Since this treatment is effective only on cells internalizing large 
amounts of boron (at least 20-30 ppm), the principal cause of its limited success mainly depends 
on the insufficient delivery of NCT compounds to the target cells. A key-issue deals with the 
measurement of the local boron concentration that is crucial to determine the optimal neutron 
irradiation time and to calculate the radiation dose. One of the problems confronting the 
successful clinical implementation of BNCT is the difficulty of quantitatively mapping the 
distribution of the boron containing molecules in patients before and during the treatment. To 
date there is no non invasive way to evaluate boron concentration in diseased and healthy 
tissues of the subject undergoing the irradiation. Thus, dose calculations are based on boron 
content values in blood, tumour, and normal tissue obtained from biodistribution studies 
performed beforehand.
4, 5 
Blood samples can be taken just before and even during irradiation to 
measure the tissue boron concentration, assuming the tumour/blood ratios assessed in previous 
biodistribution studies. However the boron distribution varies among patients and therefore 
large uncertainties exist in the tumour-to-blood boron concentration ratio. The recent 
development of more sensitive imaging techniques and molecular medicine protocols, based on 
the use of site specific agents able to carry large amounts of both therapeutic and diagnostic 
agents, can contribute to enhance BNCT efficacy and to become more competitive with the 
established tumour treatment protocols.
6
 Among the compounds developed for BNCT, much 
attention has been devoted to carboranes, icosahedral cages containing several boron atoms, 
which could increase the payload of boron in the tumour cells.
7-10
 Boron containing compounds 
can be further functionalized with lipophilic moieties in order to permit their specific and 
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efficient delivery through the incorporation in targeted nanoparticles. The synthesis of new dual 
agents for applications in MRI/BNCT where a carborane unit is linked to a lipophilic chain and to a 
Gd-DOTA complex through amidic bonds has been developed in our laboratory (AT101).
11
 
According to the synthetic design, the lipophilic probe AT101 binds to LDLs (Low Density 
Lipoproteins) and accumulates at tumor cells characterized by an up-regulation of LDL 
transporters. The exploitation of LDL as biological vectors was indeed the key to obtain a high 
concentration of B atoms/g at the tumor cells together with a good selectivity between tumor and 
healthy tissues. In vivo MR images acquisition showed that the amount of boron taken up in the 
tumor region was above the threshold required for a successful NCT treatment. More recently, with 
the purpose of simplifying the synthetic procedure but maintaining, and possibly improving, the 
favorable properties of AT101, we designed a new structure containing a triazole linker instead of 
the amidic function (MEA/01).
12
 Its adducts were tested “in vitro” on B16 melanoma cells and the 
obtained intracellular Gd/B concentration appears sufficient for further “in vivo” BNCT studies. 
An alternative promising approach to deliver efficiently boron containing agents to tumors consists 
of the use of liposomes. In fact, there are many examples in the literature of formulations containing 
boron compounds encapsulated into the aqueous cavity or, after conjugation with lipids, 
incorporated into the liposomal bilayer.
13-15
 A specific class of liposomes, named “long time 
circulating” polyethylene glycol (PEG)–coated liposomes, is able to accumulate in solid tumors as a 
consequence of microvascular permeability and defective lymphatic drainage.
16-18
 The extent of 
passive extravasation is directly dependent on the prolonged residence time of liposomes in the 
blood stream. As far as the internalization step is concerned one should note that in the absence of a 
receptor mediated mechanism, the internalization of the intact liposome into tumor cells does not 
take place. Therefore, in the absence of liposome active targeting the boron containing molecule has 
first to be released in the tumor extracellular matrix in order to allow its diffusion into cells. 
Alternatively, the active targeting of liposomes to tumor cells is obviously a promising strategy to 
improve drug delivery to tumors. To this purpose, liposomes have to be functionalized with specific 
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ligands able to bind and to internalize through receptors expressed on tumor vasculature or on 
tumor cells. Recently, Nakamura and co-workers developed liposomes containing 
mercaptoundecahydrododecaborate (BSH) in the inner aqueous cavity and 10% distearoyl boron 
lipid (DSBL) incorporated in the phospholipid bilayer.
19, 20 
The proposed system appears 
particularly efficient because the liposome shell itself contains boron in addition to the boron 
encapsulated in the aqueous cavity. Furthermore, they performed the in vivo real-time tracking of 
10% DSBL liposomes by MRI using liposomes encapsulating Gd-DOTA, observing a high signal 
intensity enhancement in the tumor region. The disadvantage of the use of therapeutic and imaging 
agents as independent molecules, is that they maintain the same biodistribution only if the liposome 
remains intact. After liposome degradation their biodistribution will be different and dependent on 
their size, hydrophilic character, residual charges, etc… In order to overcome this problem, in this 
study, a dual agent in which the imaging (Gd-DOTA) and the BNCT (carborane) components are 
part of the same molecule, is proposed. The incorporation of the molecule in the liposome bilayer 
has been pursued by a functionalization with a cholesterol residue. Cholesterol is a standard 
component of the liposome bi-layer usually introduced in the phospholipid formulation in order to 
increase the particle stability. On the contrary, complexes bearing only a palmitic chain, as the 
parent AT101 previously investigated by our group, can not be steadily incorporated in the 
liposome bi-layer and the complex may be releazed randomly. Synthetic mimics of cholesterol 
represent an important molecular tool in the fields of bioorganic/medicinal chemistry and chemical 
biology.  Furthermore, carborane cholesterol derivatives were incorporated in unilamellar liposomes 
showing selective localization in tumours
21, 22
 and might be useful vehicles for transporting boron to 
the tumor site. In this study, the liposomes embedded with MRI/BNCT dual probes have been 
functionalized with a peghilated phospholipid containing a folic acid residue at the end of the PEG 
chain, as a specific carrier to transport large amounts of B/Gd dual agents to tumor cells, in 
particular human ovarian cancer cells, overexpressing folate receptors. Finally, in order to improve 
the efficacy of the dual agent, the DOTA-monoamide ligand has been complexed with gadolinium 
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enriched in the 
157
Gd isotope (95%) that has the largest (255,000b) thermal neutron capture cross 
section among all the stable isotopes, and it is about 66 times as large as that of 
10
boron (3838 b). 
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RESULTS AND DISCUSSION 
Synthesis of B/Gd dual agent. Since the hydroxyl group of cholesterol is sterically hindered and 
then unreactive, in the first synthetic step it has been functionalized, by a nucleophilic substitution, 
with a hydroxyl propyl group in order to make easier the linkage to the carborane cage. As shown 
in, cholesterol was transformed in the corresponding mesylate (1) in quantitative yields, (as 
assessed by the detection of the signal at 2.97 ppm in the 
1
H spectrum pertinent to the mesylate 
CH3). Intermediate 1 was reacted with propan-1,3-diol in anhydrous dioxane at 120°C overnight. 
Despite the harsh applied conditions, the product was obtained in 27% yield after chromatographic 
purification, because of the steric hindrance of the alcoholic group. Alcohol 2 was then oxidized to 
the corresponding carboxylic acid, following the classical Jones reaction conditions with an overall 
yield of 78%. The formation of 3-(Cholesten-5-en-3-yloxy)-propionic acid (3,Scheme 1) was 
confirmed by the detection of a resonance at 170 ppm in the 
13
C spectrum pertinent to the carbonyl 
group. The COOH moiety was then coupled to C-(2-benzyloxy)-ethyl-C’-aminomethyl-o-carborane 
7 (prepared as previously reported).
11
 Firstly, the coupling was attempted according to the 
procedure proposed by Kamiński,23 but the desired product was not obtained. A two-step 
protocol, where the acid was activated with N-hydroxysuccinimide (NHS) in the presence of 
DCC was then applied with the formation of product 4 (64% yield after chromatograhic 
purification). 
1
H NMR analysis confirmed the proposed structure. In particular the resonance of 
the α-methylenic group shifted from 3.39 ppm in the amino derivative 7 to 4.06 ppm in the 
coupling product. 
At this point the functionalization of the other arm of the o-carborane has been tackled. As 
reported in Scheme 2, the benzylic protecting group was selectively removed by Pd/C catalyzed 
hydrogenation.
24
 Different catalyst concentrations and solvents were tested in order to avoid the 
concomitant hydrogenation of the cholesterol double bond. It was found that 5% of Pd/C in 
EtOH/CH2Cl2 2/1 provide the best conditions, affording after 24 h the desired product 5 in 92% 
overall yield. 
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Alcohol 5 was readily oxidized to the corrisponding carboxylic acid 6 by CrO3 in acetone-
sulfuric acid solution (scheme 2).  
The structure of derivative 6 was supported by the 
1
H and 
13
C NMR data. The 
1
H NMR spectrum 
showed the disappearance of the signal at 3.75 ppm assigned to the HOCH2- group, with the 
concomitant growth in the 
13
C NMR spectrum, of the signal at 172 ppm corresponding to the 
carbonyl group. 
In order to obtain the molecule containing both the BNCT and the MRI moieties, derivative 6 
was reacted with N-terbutyl-DOTAMA-C6-NH2 using the two-step procedure previously 
described for the preparation of C-(2-benzyloxyethyl)-C’-[cholesten-5-en-3-yloxy-(3-
propionacetoamidomethyl)]-o-carborane (4) (Scheme 2). Carborane 6 was then activated via 
NHS in the presence of DCC and after filtration of DCU, reacted with the suitable amine 
affording the C-[N-tert-butylDOTAMA-C6-)-carbamoylmethyl]-C’-[cholesten-5-en-3-yloxy-
(3-propionacetoamidomethyl)-o-carborane (8) in a 67% overall yield. The structure was 
completely characterized and confirmed by ESI mass spectrometry with the detection of the 
characteristic ion at 1327.87 (M + H
+
). After removal of tert-butil ester groups (CF3CO2H / 
CH2Cl2), the Gd(III) complex 10 was finally obtained by adding stoichiometric amounts of 
GdCl3 in an aquous solution of the ligand at pH 6.5 (scheme 3).  
 
Liposome preparation and characterization.  Liposomes were prepared by means of the standard 
thin lipid film hydration method
25
 using the following components: POPC, CHOL, Gd-B-AC01, 
DSPE-PEG2000, DSPE-PEG2000-Folate. Three types of liposomes containing the same amount of 
POPC (71%) and different amount of cholesterol and Gd-B-AC01, namely 15,5:7.5%, 13:10%, 
8:15%, respectively, were prepared. In order to increase the stability and limit their non specific 
phagocytic uptake, all the liposomes contain 6 % of peghilated phospholipid (DSPE-PEG2000). 
The millimolar relaxivity (21.5 MHz, 25°C) of Gd-B-AC01incorporated in the liposome 
formulation was 18.4±0.8 (mmol/L)
−1
 s
−1
. This value is relatively high as a consequence of both the 
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decrease of the molecular mobility upon the insertion in the liposome membrane and the relatively 
fast water exchange rate through the phospholipid bilayer due to the presence in the formulation of 
a high % of unsaturated phospholipids (POPC). The average liposome hydrodynamic diameter was 
125± 10 nm for all investigated formulations as detected by dynamic light scattering measurements. 
In order to accumulate the Gd-B-AC01 loaded liposome selectively at the tumor cells, 1% of a 
DSPE phospholipid conjugated to a folate residue has been added to the phospholipid formulation. 
Overexpression of folate receptors (FRs) is well established in many cancer cells (ovary, brain, 
kidney, breast and lung)
26, 27
 thus identifying this receptor as a potential target for many types of 
ligand directed cancer therapeutics.
28
 FR may be further qualified as a tumor-specific target, since it 
generally becomes accessible to intravenous administered drugs only after malignant 
transformation. Folate Receptors (FRs) are normally expressed on cancer cells up to 10
7
 FRs/cell 
but the rate of receptor recycling is relatively low.
29, 30
 Folate conjugates bind to folate receptors 
with high affinity (Kd ≈ 10
-9
 M) and they are internalized through receptor-mediated endocytosis. 
The physicochemical properties of the liposome with 1% folate-phospholipid are very similar to the 
untargeted control liposome (without folic acid).  
 
NMRD profiles. 1/T1 nuclear magnetic resonance dispersion (NMRD) profiles, over a range of 
Larmor frequencies 0.01< MHz< 70, have been recorded for an aqueous solution of Gd-B-AC01 
(0.32 mM) and compared with the profile obtained for Gd-B-AC01 embedded in the liposome 
membrane (Figure 1). Both profiles show a relaxivity hump at about 30 MHz, typical of slowly 
moving systems. The relaxivity enhancement observed with respect the free complex is limited by 
the relatively long exchange time M of the water directly coordinated to the metal ion (inner sphere 
water) as previously shown for several Gd complexes bearing a DOTA- monoamide ligand 
structure.
31, 32
 The presence of a relaxivity peak between 10 and 60 MHz of the Gd-B-AC01aqeous 
solution confirms that the complex forms stable micelles. A titration (T1 vs [Gd-B-AC01]) indicated 
a cmc lower than 15 M. The linear dependence of relaxation rates between 300 and 15 M 
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indicates that over all this concentration range the complex remains in the micellar form. Lower 
concentrations are under the detection limit of the relaxometric method.    
 
Uptake experiments on IGROV-1 cells in vitro and MRI analysis. Liposomes were tested in 
vitro on Human Ovarian Carcinoma IGROV-1 cells to evaluate the amount of Gd taken up by cells 
after 24 hours incubation by measuring the metal concentration by ICP-MS analysis. These cells 
express a significant level of FR (0.5-1 x 106 receptors/cell).33 The liposome stability, as 
demonstrated by the absence of non specific release of Gd-B-AC01to tumor cells, has been checked 
by incubating cells, for 24h at 37°C, in the presence of non targeted Gd-B-AC01/liposome 
containing increasing % of Gd-B-AC01from 7.5 to 15%. The results reported in figure 2A show 
that the amount of Gd associated non-specifically to IGROV-1 cells is directly proportional to the 
% loading of Gd-B-AC01in the liposome. This is due to the high affinity of cholesterol for cell 
membranes that causes the translocation of a small but significative % of the complex from the 
liposome to the cell membrane. By reducing the % of Gd-B-AC01with respect the other 
phospholipids, it is possible to reduce the number of released complexes bound aspecifically to the 
cell surface that can cause the decrease of the ratio between the internalized boron by tumor with 
respect the surrounding healthy cells. For these reasons the formulation containing the 7.5 % of Gd-
B-AC01has been selected to perform the FR targeting study on FR expressing IGROV-1 cells. The 
Gd moles internalized by IGROV-1 cells measured by ICP-MS after incubation in the presence of 
increasing concentration of folate-targeted liposomes were compared with those obtained using 
non-targeted ones. Figure 2B shows that increasing the concentration of targeted and non-targeted 
liposomes incubated with IGROV-1 cells, the targeted liposomes quickly reach complete saturation 
of their folate uptake. This behavior demonstrates a high affinity of folate targeted liposomes for the 
FR receptor. Moreover, it indicates that the non specific Gd-B-AC01 release from non-targeted 
liposomes does not invalidate the comparison if one works at relatively low liposome 
concentrations.  
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In order to assess whether the amount of Gd internalized in target cells is enough to permit MRI 
visualization, T1 weighted images of glass capillaries containing cellular pellets obtained by 
incubating ca. 1x10
6
 IGROV cells with increasing amounts of targeted and non targeted Gd-B-
AC01/liposomes were acquired at 1 and 7 T (Figure 3). At 1 T, there is a dominant effect of the 
long reorientational motion of the paramagnetic macromolecule that causes a dramatic relaxation 
rate increase with a consequent signal intensity enhancement increase as shown in the NMRD 
profiles of figure 1. Clearly, the SI enhancements of labeled cells measured at 1 T (SI=80% after 
5M Gd incubation) were markedly higher than those measured at 7 T (SI=45% after 5uM Gd 
incubation). The mean SI enhancement (%) of the target tissues was calculated according to the 
Equation (1):  
 
SI % Enhancement = ((mean SIPOST - mean SIPRE) / mean SIPRE) x 100 
 
 The recorded SI of targeted liposome in both cell lines is higher in respect to non-targeted ones. 
This demonstrates the specific accumulation of folate targeted liposomes in tumor cells with respect 
to control liposomes. The amount of internalized boron measured by ICP-MS was 38 and 9 ppm for 
folate-targeted and non-targeted liposomes, respectively. The former amount is significantly higher 
than the minimum boron concentration necessary to perform BNCT. We can conclude that Gd-B-
AC01loaded liposomes are efficient carriers for the delivery of MRI/BNCT probes to tumor cells. 
 
BNCT treatment of IGROV-1 cells.  
Figure 4 shows the percent of cells survived to the neutron irradiation. Two cell controls have been 
used in this experiment. The first did not receive any neutron irradiation and boron and the second 
control was irradiated without boron. The number of survived cells was significantly lower when 
cells have been irradiated after folate-targeted GdB10-AC01/liposomes internalization whereas in 
the absence of boron the effect of neutron irradiation is almost negligible. Furthermore, the 
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proliferation rate of the boron treated cells survived to the irradiation is significantly lower than that 
measured on both control cells.   
Although the cells have not been completely killed, the purpose of the experiments has been 
satisfied because these measurements were meant to verify that the new formulations had a 
potentiality as vectors for BNCT. Further studies with dose escalation are planned. 
 
Conclusions.  
In summary, the dual MRI/BNCT probe described in this paper can be exploited to accumulate B 
and Gd at target tumor cells. The new formulation has shown to have relevant characteristics: 1) 
ability to selectively concentrate high amounts of B at the tumor cells, 2) possibility to quantify the 
boron concentration by MRI; 3) the cholesterol versatility to be incorporated in different particles 
can be exploited to perform a multi-step treatment based on the administration of different drugs 
targeted to different overexpressed receptors. 4) The amount of internalized B is enough to perform 
an efficient BNCT treatment and the selective target of B using folate-targeted liposomes is 
reported to reduce significantly the uptake by healthy cells in the surrounding regions. 5) The use of 
liposomes as a nanoplatform for the delivery of Gd and B agents will permit the simultaneous 
delivery of standard anti-tumor drugs (such as doxorubicin) in order to improve the efficacy of the 
treatment.   
EXPERIMENTAL PROCEDURES 
General Methods 
Flasks and all equipments used for the generation and reaction of moisture-sensitive compounds 
were dried by electric heater under Ar. THF was distilled from benzophenone ketyl, anhydrous 
Et2O was distilled from LiAlH4 and anhydrous CH2Cl2 from CaH2 prior to use. BuLi (1.6 M in 
hexanes) was obtained from Aldrich. (Bmim)
+
Cl
-
 was purchased from Solvent Innovation 
GmbH. Decaborane was bought from KATCHEM spol. s r. o. All commercially obtained 
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reagents and solvents were used as received. Product were purified by preparative column 
chromatography on Macherey Nagel silica gel for flash chromatography, 0,04-0,063 mm/ 230-
400 mesh. 
Reactions were monitored by TLC using Silica gel on TLC-PET foils Fluka, 2-25 mm, layer 
thickness 0.2 mm, medium pore diameter 60 Å. Carboranes and their derivatives were 
visualized on TLC plates using a 5% PdCl2 aqueous solution in HCl. 
1
H NMR spectra were 
recorded at 200 MHz, 
13
C NMR spectra at 50.2 MHz. Data were reported as follows: chemical 
shifts in ppm from tetramethylsilane as internal standard, integration, multiplicity (s = singlet, d 
= doublet, t = triplet, q = quartet, dd = double-doublet, m = multiplet, br = broad), coupling 
constants (Hz), and assignment. 
13
C NMR spectra were measured with complete proton 
decoupling. Chemical shifts were reported in ppm from the residual solvent as an internal 
standard. GC-MS spectra were obtained on a mass selective detector HP 5970 B instrument 
operating at an ionizing voltage of 70 eV connected to a HP 5890 GC with a cross linked 
methyl silicone capillary column (25 m X 0.2 mm X 0.33 mm film tickness). ESI MS spectra 
were obtained on a Waters micromass ZQ spectrometer equipped with ESI ion source. IR 
spectra were recorded on a Perkin Elmer BX FT-IR. C-(2-benzyloxyethyl)-C’-aminomethyl-o-
carborane (7) and N-tert-ButylDOTAMA-C6-NH2 were synthesized as described in literature 
and their spectroscopic data corresponded with those reported.
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(3β)-colest-5-en-3-methanesulfonate (1). Cholesterol (12.9 mmol, 5 g) was dissolved in 100 mL 
of anhydrous Et2O and cooled to 0 
◦
C in a 250 mL three necked round bottom flask, then Et3N (1.5 
equiv, 19.4 mmol, 2.7 mL) followed by MsCl (19.4 mmol, 1.5 mL) were added. The reaction 
mixture was stirred for 1 h then quenched with H2O and extracted with Et2O (3 x 30 mL). The 
combined extracts were washed with H2O (2 x 30 mL), dried and evaporated under reduced 
pressure leaving 5.9 g (98 %) of a pale yellow oil which was at once used for the following 
reaction. Found C, 72.37; H, 10.40; S, 6.92. Calc. for C28H48O3S: C, 72.36; H, 10.41; S, 6.90. 
νmax (neat)/cm
-1
 2940, 1467, 1353, 1172; δH (200 MHz; CDCl3, Me4Si): 0.65 (3H, s, 
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CH3CH(CH2)3), 0.70-2.05 (40H, m, CH3CH(CH2)3, (CH3)2CH, CH3 ring, CH2 ring, CH ring), 2.50 
(2H, m, CH2CH=C), 3.03 (1H, m, CH3SO2), 4.50 (1H, m, CHO), 5.41 (1H, bd, CH2CH=C, J = 5.5 
Hz) ; δc (50.2 MHz; CDCl3, Me4Si): 11.6 (CH3), 18.5 (CH), 18.9 (CH), 20.8 (CH2), 22.4 (CH), 22.6 
(CH), 23.6 (CH2), 24.0 (CH2), 27.7 (CH3), 28.0 (CH2), 28.7 (CH2), 31.5 (CH), 31.6(CH2), 35.5 
(CH), 35.9 (CH2), 36.1 (CH2), 36.6 (CH), 38.4 (CH2), 38.9 (CH2) , 39.3 (CH2), 39.4 (CH2), 42.1 
(Cq), 49.7 (CH3), 55.9 (CH), 56.4 (CH) , 81.7 (CH) , 123.4 (Cq), 138.5 (CH). m/z (ESI+) 465.33 
[M + H]
+
. 
 
 3-((3β)-colest-5-en-3-yloxy)-propanol (2). According to literature procedure,25 (3β)-colest-5-en-3-
methanesulfonate (1) (12.8 mmol, 5.93 g) was dissolved in 100 mL of anhydrous dioxane in a 250 
mL three necked round bottom flask. 1,3-Propandiol (319 mmol, 24.3 g) was added and the 
resulting mixture was stirred overnight at 120 °C. Then the solution was cooled down at room 
temperature and solvent was removed under reduced pressure. The residue was dissolved in 50 mL 
of CH2Cl2 and washed with H2O. The organic layer was separated, washed with NaHCO3 (1 X 50 
mL), water (1 X 50 mL), and brine (1 X 50 mL), dried over anhydrous K2CO3, and evaporated 
under reduce pressure. The crude was purified on silica gel (petroleum ether/diethyl ether 50/50) 
giving 1.54 g (27 %) of a white solid. Found C, 81.05; H, 11.80. Calc. for C30H52O2: C, 81.02; H, 
11.79. νmax (neat)/cm
-1
 3434, 2934, 2098, 1642; δH (200 MHz; CDCl3, Me4Si): 0.67 (3H, s, 
CH3CH(CH2)3), 0.70-2.49 (42H, m, CH3CH(CH2)3, (CH3)2CH, CH3 ring, CH2 ring, CH ring), 2.60 
(1H, bs, OH), 3.19 (1H, tt, J = 8.5, 5.2, CHO), 3.67 (2H, t, J = 5.8 Hz, HOCH2CH2O), 3.77 (2H, t, J 
= 5.4 Hz, HOCH2CH2O), 5.33 (1H, bd, J = 5.2 Hz, CH2CH=C); δc (50.2 MHz, CDCl3, Me4Si): 11.6 
(CH3), 18.5 (CH3), 19.0 (CH3), 20.8 (CH2), 22.3 (CH), 22.5 (CH), 23.8 (CH2), 24.0 (CH2), 27.6 
(CH), 28.0 (CH), 31.6 (CH2), 32.3 (CH2), 35.6 (CH), 36.0 (CH2), 36.4 (Cq), 37.0 (CH2), 38.8 
(CH2), 39.2 (CH2), 39.5 (CH2), 42.0 (Cq), 49.9 (CH), 56.0(CH) , 56.4 (CH), 60.2 (CH2), 65.8 
(CH2), 76.4 (CH), 121.3 (CH), 140.3 (Cq); m/z (ESI+) 467.70 [M + Na]
+
. 
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3-(Cholesten-5-en-3-yloxy)-propionic acid (3). 3-((3β)-colest-5-en-3-oxy)-propanol (2) (0.63 g, 
1.41 mmol) was dissolved in 21 mL of acetone, then a 3 M solution of CrO3 (4 equiv, 5.6 mmol, 
0.56 g) in H2SO4 (7 mL) was added dropwise at 0°C. The reaction mixture was stirred overnight 
at rt, then quenched with H2O. The solvent was evaporated under reduced pressure and the 
mixture was extracted with CH2Cl2 (5  10 mL), the organic layers were washed once with 
brine (1 X 10 mL), dried and evaporated giving 0.49 g (76 %) of white solid. Found C, 78.57; H, 
11.00. Calc. for C30H50O3: C, 78.55; H, 10.99. νmax (neat)/cm
-1
 3400, 2938, 1715; δH (200 MHz; 
CDCl3, Me4Si): 0.68 (3H, s, CH3CH(CH2)3), 0.70-2.05 (38H, m, CH3CH(CH2)3, (CH3)2CH, CH3 
ring, CH2 ring, CH ring), 2.05-2.50 (2H, m, CH2CH2COOH), 2.62 (2H, t, J = 6.4 Hz, CH2COOH), 
3.21 (1H, m, CHO), 3.76 (2H, t, J = 6.4 Hz, CH2OH), 5.35 (1H, bd, J = 5.2 Hz, CH2CH=C); δc 
(50.2 MHz, CDCl3, Me4Si): 11.6 (CH3), 18.6 (CH3), 19.1 (CH3), 20.8 (CH2), 22.3 (CH3), 22.6 
(CH3), 23.6 (CH2), 24.0 (CH2), 27.8 (CH2), 28.0 (CH), 31.6 (CH2), 31.8 (CH), 35.0 (CH2), 35.6 
(CH), 36.0 (CH2), 36.6 (CH2), 36.9 (CH2), 38.7 (CH2), 39.4 (CH2), 39.5 (CH2), 42.1 (Cq), 49.9 
(CH), 55.9 (CH), 56.6 (CH), 62.8 (CH2), 79.3 (CH), 121.5 (CH), 140.4 (Cq), 176.9 (Cq); m/z 
(ESI+) 459.72 [M + H]
+
.  
 
C-(2-Benzyloxyethyl)-C’-[cholesten-5-en-3-yloxy-(3-propionacetoamidomethyl)]-o-carborane 
(4). In a 100 mL three necked round bottom flask, 3-(cholesten-5-en-3-yloxy)-propionic acid (3) 
(1.27 mmol, 0.58 g) was dissolved in 40 mL of dry CH2Cl2 then C-(benzyloxy)-ethyl-C’-
aminomethyl-o-carborane (1.26 mmol, 0.38 g) and N,N'-dicyclohexylcarbodiimide (1.51 mmol, 
0.31 g) were added at room temperature. The resulting mixture was stirred at room temperature 
overnight. The reaction mixture was filtered and was washed with 3% NaHCO3 (1 X 30 mL) and 
brine (1 X 30 mL). The organic layer was dried, the solvent evaporated under reduced pressure. The 
crude was purified on silica gel (petroleum ether/ diethyl ether 80/20) giving 0.7 g (73 %) of a 
white solid. 
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M.p.= 76-79 °C. Found C, 67.45; H, 9.84; S. Calc. for C42H73B10NO3: C, 67.43; H, 9.83. νmax 
(neat)/cm
-1
 3332, 2581, 1660; δH (200 MHz; CDCl3, Me4Si): 0.68 (3H, s, CH3CH(CH2)3), 0.70-2.49 
(40H + 10H, m, CH3CH(CH2)3, (CH3)2CH, CH3 ring, CH2 ring, CH ring, BH), 2.40 (2H, t, J = 5.2 
Hz, CH2CH2CONH), 2.69 (2H, t, J = 6.0 Hz, PhCH2OCH2CH2),  3.23 (1H, m, CHO), 3.68 (4H, m, 
PhCH2OCH2CH2, OCH2(CH2)2CONH), 4.07 (2H, d, J = 6.4 Hz, CONHCH2),  4.51 (2H, s, 
PhCH2O), 5.38 (1H, bd, J = 4.8 Hz, CH2CH=C), 7.31 (1H, t, J = 6.0 Hz, CONH), 7.39 (5H, bs, Ph); 
δc (50.2 MHz; CDCl3, Me4Si): 11.6 (CH3), 18.6 (CH3), 19.2 (CH3), 20.9 (CH2), 22.4 (CH3), 22.7 
(CH3), 23.7 (CH2), 24.1 (CH2), 27.8 (CH), 28.1 (CH2), 31.7 (CH), 31.8 (CH2), 35.1 (CH2), 35.6 
(CH2), 36.0 (CH), 36.7 (CH2), 36.8 (Cq), 36.9 (CH2), 38.8 (CH2), 39.3 (CH2), 39.6 (CH2), 41.2 
(CH2), 42.1 (Cq), 50.0 (CH), 56.0 (CH), 56.6 (CH), 63.2 (CH2), 68.2 (CH2), 72.9 (CH2), 78.4 (Cq), 
79.1 (Cq), 79.4 (CH), 121.9 (CH), 127.6 (CH), 127.7 (CH), 128.3 (CH), 137.3 (Cq), 140.1 (Cq), 
171.2 (Cq); m/z (ESI+) 749.15 [M + H]
+
.  
 
C-(Hydroxyethyl)-C’-[cholesten-5-en-3-yloxy-(3-propionacetoamidomethyl)]-o-carborane (5) 
In a 50 mL two necked round bottom flask, C-(2-Benzyloxyethyl)-C’-[cholesten-5-en-3-yloxy-(3-
propionacetoamidomethyl)]-o-carborane (4) (0.18 g, 0.24 mmol)  was dissolved in 20 mL of a 
mixture of EtOH-CH2Cl2 (50-50), then Pd/C (10%) was wet with few drops of water and added. 
The reaction mixture was stirred overnight at rt in a H2 saturated atmosphere, then filtered and 
the solvent was evaporated under reduced pressure giving 0.14 g (88 %) of a white solid.  M.p.= 
103-106 °C. Found C, 63.90; H, 10.25; S. Calc. for C35H67B10NO3: C, 63.88; H, 10.26; νmax 
(neat)/cm
-1
 3433, 2583, 1655, 1587; δH (200 MHz; CDCl3, Me4Si): 0.70 (3H, s, CH3CH(CH2)3), 
0.80-2.40 (41H + 10H, m, CH3CH(CH2)3, (CH3)2CH, CH3 ring, CH2 ring, CH ring, OH, BH), 2.50 
(2H, t, J = 5.0 Hz, HOCH2CH2), 2.63 (2H, t, J = 6.2 Hz, CH2CH2CONH),  3.24 (1H, m, CHO), 3.73 
(2H, t, J = 6.4 Hz, OCH2(CH2)2CONH), 3.80 (2H, t, J = 5.2 Hz, HOCH2CH2), 4.11 (2H, d, J = 6.6 
Hz, CONHCH2),  5.39 (1H, bs, CH2CH=C), 7.36 (1H, bt, CONH); δc (50.2 MHz; CDCl3, Me4Si): 
11.6 (CH3), 18.5 (CH3), 19.2 (CH3), 20.9 (CH2), 22.4 (CH3), 22.6 (CH3), 23.6 (CH2), 24.1 (CH2), 
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27.8 (CH), 28.0 (CH2), 31.7 (CH), 31.8 (CH2), 33.7 (CH), 35.6 (CH2), 36.0 (CH), 36.6 (CH2), 36.8 
(Cq), 37.4 (CH2), 38.7 (CH2), 39.3 (CH2), 39.5 (CH2), 41.4 (CH2), 42.1 (Cq), 49.9 (CH), 55.9 (CH), 
60.8 (CH2), 63.1 (CH2), 78.1 (Cq), 79.0 (Cq), 79.6 (CH), 122.0 (CH), 140.0 (Cq), 171.7 (Cq); m/z 
(ESI+) 659 [M + H]
+
. 
 
[Cholesten-5-en-3-yloxy-(3-propionacetoamidomethyl)-o-carboranyl]-acetic acid (6) C-
(Hydroxyethyl)-C’-[cholesten-5-en-3-yloxy-(3-propionacetoamidomethyl)]-o-carborane (5) (0.48 
g, 0.73 mmol) was dissolved in 21 mL of acetone, then a 3 M solution of CrO3 (4 equiv, 2.9 
mmol, 0.29 g) in H2SO4 (7 mL) was added carefully at 0 °C. The reaction mixture was left 
overnight at rt, then quenched with H2O. The solvent was evaporated under reduced pressure 
and the mixture was extracted with CH2Cl2 (5  10 mL), the organic layers were washed once 
with  brine (1  10 mL), dried and evaporated giving 0.42 g (85%) of pale yellow oil. Found C, 
62.53; H, 9.76; N, 2.09. Calc. for C35H65B10NO4: C, 62.56; H, 9.75, N, 2.08; νmax (neat)/cm
-1
 
3316, 2932, 2613, 2577, 1739, 1586, 1552; δH (200 MHz; CDCl3, Me4Si): 0.70 (3H, s, 
CH3CH(CH2)3), 0.80-2.45 (41H + 10H, m, CH3CH(CH2)3, (CH3)2CH, CH3 ring, CH2 ring, CH ring, 
BH), 2.63 (2H, t, J = 5.6 Hz, CH2CH2CONH), 3.24 (1H, m, CHO), 3.79 (2H, t, J = 5.6 Hz, 
OCH2(CH2)2CONH), 4.11 (2H, d, J = 4.4 Hz, CONHCH2), 5.39 (1H, bs, CH2CH=C δc (50.2 MHz; 
d6DMSO, Me4Si): 12.3 (CH3), 19.0 (CH3), 19.6 (CH3), 22.9 (CH2), 23.1 (CH3), 23.2 (CH3), 24.5 
(CH2), 25.9 (CH2), 28.0 (CH), 29.7 (CH2), 32.0 (CH), 33.9 (CH2), 35.8 (CH), 36.2 (CH2), 36.3 
(CH), 36.9 (CH2), 37.0 (Cq), 39.0 (CH2), 40.6 (CH2), 41.6 (CH2), 42.4 (CH2), 42.7 (CH2), 43.1 
(Cq), 48.1 (CH), 50.2 (CH), 56.2 (CH2), 56.8 (CH2), 76.0 (Cq), 78.7 (Cq), 81.6 (CH), 121.5 (CH), 
141.0 (Cq), 168.9 (Cq); 171.3 (Cq); m/z (ESI+) 696 [M + Na + H]
+
. 
 
C-[N-tert-ButylDOTAMA-C6-)-carbamoylmethyl]-C’-[cholesten-5-en-3-yloxy-(3-
propionacetoamidomethyl)-o-carborane (8). According to the previous procedure described for 
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compound 3, [cholesten-5-en-3-yloxy-(3-propionacetoamidomethyl)-o-carboranyl]-acetic acid (6) 
(0.2 g, 0.29 mmol) was reacted with N-tert-butylDOTAMA-C6-NH2 (0.19 g, 0.29 mmol). The crude 
was purified on silica gel (eluant: CH2Cl2-MeOH 96-4, then CH2Cl2-MeOH 80-20) affording 0.15 
g (42%) of pale yellow oil. Found C, 62.57; H, 9.82; N, 7.41. Calc. for C69H129B10N7O10: C, 
62.55; H, 9.81, N, 7.40; νmax (neat)/cm
-1
 3294, 2933, 2575, 1730, 1665, 1552;  δH (200 MHz; 
CDCl3, Me4Si): 0.70 (3H, s, CH3CH(CH2)3), 0.80-2.50 (78H + 10H, m, CH3CH(CH2)3, (CH3)2CH, 
CH3 ring, CH2 ring, CH ring, NHCH2CH2NH, NHCOCH2(CH2)4CH2NHCO, BH), 1.50 (27H, s, 
COOtBu), 3.10-3.80 (13H, m, CH2COOtBu, NHCOCH2(CH2)4CH2NHCO, CHO), 3.79 (2H, bt, 
OCH2(CH2)2CONH), 4.11 (2H, d, J = 6.2 Hz, CONHCH2),  5.39 (1H, bd, CH2CH=C), 8.20 (1H, 
bs, NHCO), 8.70 (2H, m, 2 X NHCO);  δc (50.2 MHz; CDCl3, Me4Si): 11.6 (CH3), 18.5 (CH3), 19.3 
(CH3), 20.9 (CH2), 22.4 (CH3), 22.7 (CH3), 23.7 (CH2), 24.1 (CH2), 25.2 (CH2), 27.8 (9 X CH3), 
28.4 (CH2), 28.4 (CH2), 28.5 (CH2), 29.5 (CH2), 31.6 (CH), 31.7 (CH2), 32.9 (CH2), 35.6 (CH), 
36.0 (CH2), 36.9 (Cq), 37.1 (CH2), 38.1 (CH2), 38.5 (CH2), 38.9 (CH2), 39.3 (CH2), 39.6 (CH2), 
41.4 (CH2), 41.6 (CH2), 42.0 (2 X CH2), 46.0 – 54.0 (8  CH2), 50.0 (CH), 55.4 (2  CH2), 56.0 
(CH), 56.6 (CH), 57.0 (Cq), 63.8 (2 X CH2), 65.8 (Cq), 75.5 (Cq), 79.0 (2 X CH), 80.0 (Cq), 81.7 
(Cq), 81.8 (Cq), 121.7 (CH), 140.7 (Cq), 166.3 (Cq), 171.1 (Cq), 171.3 (Cq), 171.4 (Cq), 171.9 
(Cq), 172.2, (Cq); m/z (ESI+) 1350 [M +  Na + H]
+
.  
C-[DOTAMA-C6-)-carbamoylmethyl]-C’-[cholesten-5-en-3-yloxy-(3-
propionacetoamidomethyl)-o-carborane (9). In a 25 mL round bottom flask, 247 mg (0.186 
mmol) of C-[N-tert-ButylDOTAMA-C6-)-carbamoylmethyl]-C’-[cholesten-5-en-3-yloxy-(3-
propionacetoamidomethyl)-o-carborane (8) were cooled to 0 °C, dissolved in 5 mL of a mixture 
of CF3COOH-CH2Cl2 (50-50) and stirred for 4 h at rt. After evaporation of CF3COOH-CH2Cl2,  
204 mg (1.99 mmol) of viscous colorless oil were obtained (95%) . Found C, 59.21; H, 9.17; N, 
8.49. Calc. for C57H105B10N7O2: C, 59.19; H, 9.15, N, 8.48; νmax (neat)/cm
-1
 3390, 2931, 2581, 
1741, 1676, 1586; δH (400 MHz; CD3SOCD3, Me4Si): 0.65 (3H, s, CH3CH(CH2)3), 0.80-2.40 (51H 
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+ 10H, m, CH3CH(CH2)3, (CH3)2CH, CH3 ring, CH2 ring, CH ring, NHCH2CH2NH, 
NHCOCH2(CH2)4CH2NHCO, BH), 3.10-3.80 (13H, m, CH2COOtBu, 
NHCOCH2(CH2)4CH2NHCO, CHO), 3.79 (2H, bt, OCH2(CH2)2CONH), 4.00 (2H, d, J = 6.2 Hz, 
CONHCH2),  5.30 (1H, bs, CH2CH=C), 7.30 (1H, m, NHCO), 8.60 (2H, m, 2 X NHCO);  δc (100.4 
MHz; CD3SOCD3, Me4Si): 11.6 (CH3), 18.5 (CH3), 19.3 (CH3), 20.8 (CH2), 22.4 (CH3), 22.7 
(CH3), 23.1 (CH2), 23.8 (CH2), 24.7 (CH2), 28.4 (CH2), 28.4 (CH2), 28.5 (CH2), 29.5 (CH2), 31.6 
(CH), 31.7 (CH2), 32.9 (CH2), 35.6 (CH), 36.0 (CH2), 36.9 (Cq), 37.1 (CH2), 38.1 (CH2), 38.5 
(CH2), 38.9 (CH2), 39.3 (CH2), 39.6 (CH2), 41.4 (CH2), 41.6 (CH2), 42.0 (2 X CH2), 46.0 – 54.0 (8 
 CH2), 50.0 (CH), 55.4 (2  CH2), 56.0 (CH), 56.6 (CH), 57.0 (Cq), 63.8 (2 X CH2), 65.8 (Cq), 
75.5 (Cq), 79.0 (2 X CH), 80.0 (Cq), 121.7 (CH), 140.7 (Cq), 166.3 (Cq), 171.1 (Cq), 171.3 (Cq), 
171.4 (Cq), 171.9 (Cq), 172.2, (Cq); m/z (ESI+) 1350 [M +  Na + H]
+
. 
 
Gd(III)-C-[N-(DOTAMA-C6)carbamoylmethyl]-C’-2-[1,3-bis(hexadecyloxy)propan-2-
yloxy]acetoamidomethyl-o-caborane complex (10). In a 100 mL round bottom flask, 70 mg of 
C-[DOTAMA-C6-)-carbamoylmethyl]-C’-[cholesten-5-en-3-yloxy-(3-propionacetoamidomethyl)-
o-carborane (9) (0.055 mmol) and 1 equivalent of GdCl3 were dissolved in water at rt. The pH 
solution was checked and maintained to 6.5 by 1 M NaOH aqueous solution. The solution was 
stirred 24h, then the pH was adjusted to 8.5 by 1 M NaOH aqueous solution and the mixture was 
stirred for 2 h, then filtered over 0.2 mm syringe filter, the pH was adjusted to 7 by a 1 M HCl 
aqueous solution and the solvent evaporated. Inorganic salts were removed by gel filtration on 
Sephadex® G10 column. The solvent was removed affording 63 mg of complex (0.043 mmol, 
40%). Found C, 46.68; H, 7.88; S. Calc. for C12H24B10O2: C, 46.73; H, 7.84; m/z (ESI+) 
1451.90 [M + H]
+
.  
 
Liposome preparation and characterization. 
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All the phospholipids used in the liposome preparation (POPC: 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-
Phosphocholine, DSPE-PEG 2000 Methoxy: 1,2-Distearoyl-sn-Glycero-3-Phosphoethanolamine-
N[Methoxy(Polyethylene Glycol)-2000] Ammonium Salt, DSPE-PEG 2000-Folate {1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-[folate(polyethylene glycol)-2000] ammonium salt} were purchased 
from Avanti Polar Lipids (Alabaster, AL). Cholesterol (Chol) was purchased from Sigma-Aldrich
 
(St. Louis, MO). Gd-AC101 was synthesized according to the above procedure. Liposomes were 
prepared by following the thin lipid film hydration method.
34, 35  
The following liposomes formulation 
were prepared using POPC:Chol:Gd-B-AC01:DSPE-PEG2000 Methoxy:DSPE-PEG2000-Folate;  
Lipo-Ctrl 1:71:8:15:6:0 molar ratio. Lipo-Ctrl 2: 71:13:10:6:0 molar ratio. Lipo-Ctrl 3: 
71:15,5:7,5:6:0 molar ratio. Liposomes with Folate  (Lipo-Folate) were prepared adding 1% molar 
ratio of DSPE-PEG 2000 Folate  in all previous described formulations; moreover DSPE-PEG 2000 was 
added in 5% molar ratio instead of 6%.  Briefly, all lipids were dissolved in chloroform and the organic 
solution was slowly evaporated for removing the solvent until a thin film was formed. The film was 
then hydrated at 55°C with 1.5 ml of a saline buffer containing 5mM Hepes and 150mM NaCl, 
pH=7.4 (HBS). The suspension of multilamellar vesicles (MLV) was extruded (Lipex extruder, 
Northern Lipids Inc., Canada) four times on polycarbonate filters with a pore diameter of 400 nm, 
four times on a 200 nm and three times on 100 nm filter. The final liposome suspension was 
dialyzed two times at 4°C against a 100-fold volume of TBS. The amount of Gd-B-
AC01incorporated  in the liposome was determined by 
1
H NMR T1 measurement at 21.5 MHz, 
25°C (Stelar Spinmaster, Mede, Italy) of the mineralized complex solution (in HCl 6M at 120 °C 
for 16 h). The hydrated mean diameter of liposomes was determined using a Malvern dynamic 
light-scattering spectrophotometer (Malvern Instruments, Malvern, UK). All samples were analyzed 
at 25°C in filtered (cutoff= 30 nm) PBS buffer (pH=7).  The polydispersity index (PDI) for all the 
liposomes prepared in this work was smaller than 0.2. The liposomes were used within two weeks 
from the preparation and stored at 4°C under argon.  
 
22 
 
1
H Relaxation rate measurements. The longitudinal water proton relaxation rates were measured 
on the Stelar Spinmaster spectrometer (Stelar, Mede, Italy) operating at 21.5 MHz by means of the 
standard inversion recovery technique (16 experiments, 2 scans). A typical 90j pulse width was 3.5 
ms and the reproducibility of the T1 data was ± 0.5%. The 1/T1 nuclear magnetic relaxation 
dispersion (NMRD) profiles of water protons were measured over a continuum of magnetic field 
strength from 0.00024 to 0.5 T (corresponding to 0.01–20 MHz proton Larmor frequency) on the 
fast field-cycling relaxometer (Stelar Spinmaster FFC 2000; Stelar) equipped with a silver magnet. 
The relaxometer operates under complete computer control with an absolute uncertainty in the 1/T1 
values of ± 1%. The typical field sequences were used the nonpolarized sequence between 40 and 8 
MHz and prepolarized sequence between 8 and 0.01 MHz. The observation field was set at 13 
MHz. Sixteen experiments of two scans each were used for the T1 determination for each field. 
 
Cell culture and uptake experiments. Human ovarian carcinoma cell line (IGROV-1) cell line 
was kindly provided by Dr. Claudia Cabella (Bracco Imaging, Colleretto Giacosa TO).  IGROV-1 
cells were cultured in RPMI (Lonza) supplemented with 10% (v/v) FBS, 2 mM glutamine, 100 U 
ml
−1
 penicillin, and 100 U ml
−1
 streptomycin. Cells were incubated at 37 °C in a humidified 
atmosphere of 5% CO2. At 80% confluence, cells were detached with 0,02% EDTA (Lonza). For 
the in vitro uptake experiments, about 4,5×10
5
 of IGROV were seeded in 6 cm diameter culture 
dishes. After 6 h, medium was removed and it was replaced with RPMI w/o Folate. After 24h, cells 
were incubated for 24 h with Lipo-Folate or Lipo-Ctrl. At the end of incubation, cells were washed 
three times with 5 ml ice-cold PBS, detached with 0.05% trypsin and 0.02% EDTA in PBS  and 
transferred into glass capillaries for MRI analysis (see below). Gd content of IGROV-1 cells was 
determined using inductively coupled plasma mass spectrometry (ICP-MS) (Element-2; Thermo-
Finnigan, Rodano, Milan, Italy). Sample digestion was performed with 2 ml of concentrated HNO3 
(70%) under microwawe heating (Milestone MicroSYNTH Microwave labstation equipped with an 
optical fiber temperature control and HPR-1000/6 M six position high pressure reactor, Bergamo, 
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Italy). After digestion, sample volumes were brought to 3 ml with ultrapure water and samples were 
analyzed by ICP-MS. Protein concentration was determined from cell lysates by the Bradford assay, 
using bovine serum albumin as standard. 
 
MRI. MR images were acquired at 1 and 7 T field. MR images at 1 T were acquired with an Aspect 
M2 High Performance MRI System (Aspect Magnet Technologies Ltd, Netanya, Israel) consisting 
of a NdFeB magnet, equipped with a 35 mm solenoid Tx/Tr coil of inner diameter 35 mm. This 
system is equipped with fast gradient coils (gradient strength, 450 mT m−1 at 60 A; ramp time, 250 
μs at 160 V) with a field homogeneity of 0.2–0.5 gauss. MR images at 7T were acquired on a 
Bruker Avance300 spectrometer equipped with a Micro 2.5 microimaging probe (Bruker BioSpin, 
Ettlingen, Germany) using two birdcage resonators with 30 and 10 mm inner diameter.  
For recording MR images in vitro, cells were centrifuged at the bottom of glass capillaries placed in 
a phantom embedded of high gelling agarose gel (1% in PBS). MR images were acquired using a 
standard T1weighted multislice spin echo sequence, using the following parameters: TR/TE/NEX 
250/4/6, resolution 78 μm, slice thickness 1 mm at 7 T and TR/TE/NEX 250/7/16, resolution 78 
μm, slice thickness 1 mm at 1 T, respectively. At both field strengths a standard saturation recovery 
protocol was used to measure T1 relaxation times. 
 
Cells irradiation 
Seven flasks, four with IGROV-1 cells previously incubated for 24h in presence of folate targeted 
GdAC01/liposomes, at a 10M Gd concentration, and three with non-treated control cells were 
irradiated in the thermal column of the TRIGA Mark II reactor at University of Pavia, Italy. The 
cells cultured in presence of liposomes were washed with cold PBS before irradiation. At the end of 
the irradiation, the medium was removed, it was replaced with RPMI and flasks were placed at 37 
°C in a humidified atmosphere of 5% CO2.  
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The irradiation position had been previously characterized from the point of view of neutron flux 
distribution by means of thin activation foils.
35
 At a reactor power of 250 kW the thermal neutron 
flux in air in that position is (1.170.03).1010cm-2 s-1, while the epithermal and fast components are 
at least two orders of magnitude lower. The flux is roughly constant (less than 1%) along the 
vertical direction thus the flasks were superposed and irradiated at the same time.  The irradiation 
time has been fixed at 15 minutes at a reactor power of 30 kW, corresponding to a thermal neutron 
fluence of 1.26·10
12
 cm
-2
. The radiation dose absorbed by cells treated with 10 M was 6.2 Gy and 
the dose absorbed by control cells was 0.6 Gy.  
 
Proliferation assay. The day after irradiation cells were detached with 0,02% EDTA and trypan 
blue exclusion test of cell viability was performed. Then, around 6x10
5
 IGROV-1 cells from each 
differently treated flask were seeded in 10 cm diameter culture dishes. After 1, 2, 3 and 4 days, cells 
were washed with PBS, detached with 0.05% trypsin and 0.02% EDTA in PBS and transferred into 
falcon tubes. Then, cells were sonicated for 30” at 30% power in ice and protein concentration from 
cell lysates was determined by the Bradford method, using bovine serum albumin as standard. 
 
 
 
 
Acknowledgments. This research was performed in the framework of the EU COST Action 
TD1004, and supported by MIUR (PRIN 2009235JB7), by the University of Torino (code 
D15E11001710003 project: Innovative Nanosized Theranostic Agents), by the University of 
Genova (Progetto San Paolo; Title: Validazione di molecole per il rilascio tumore specifico di 
farmaci e la valutazione contestuale della risposta mediante imaging funzionale), and by Consorzio 
Interuniversitario di Ricerca  in Chimica dei Metalli dei Sistemi Biologici (CIRCMSB). We thank 
Franco Fedeli for the synthesis of N-tert-ButylDOTAMA-C6-NH2 
25 
 
 
Supporting Information description, 
1
H NMR, 
13
C NMR and DEPT spectra of products 1-5 and 
8.  This material is available free of charge via the Internet at http://pubs.acs.org.” 
 
Footnotes 
Author Contributions. D.Alberti and A.Toppino contributed equally. 
 
The authors declare no competing financial interest. 
 
26 
 
References. 
 
1. R. F. Barth, J.  Neuroonc., 2003, 62, 1-5. 
2. R. F. Barth, J. A. Coderre, M. G. H. Vicente and T. E. Blue, Clin. Canc. Res., 2005, 11, 
3987-4002. 
3. M. F. Hawthorne and M. W. Lee, J. Neuroonc., 2003, 62, 33-45. 
4. J. Laakso, M. Kulvik, I. Ruokonen, J. Vahatalo, R. Zilliacus, M. Farkkila and M. Kallio, 
Clin. Chem., 2001, 47, 1796-1803. 
5. M. Kortesniemi, T. Seppala, I. Auterinen and S. Savolainen, Appl. Rad. Isot., 2004, 61, 823-
827. 
6. S. Geninatti-Crich, A. Deagostino, A. Toppino, D. Alberti, P. Venturello and S. Aime, Anti-
Cancer Agents Med. Chem., 2012, 12, 543-553. 
7. A. H. Soloway, W. Tjarks, B. A. Barnum, F. G. Rong, R. F. Barth, I. M. Codogni and J. G. 
Wilson, Chem. Rev., 1998, 98, 1515-1562. 
8. J. F. Valliant, K. J. Guenther, A. S. King, P. Morel, P. Schaffer, O. O. Sogbein and K. A. 
Stephenson, Coord. Chem. Rev., 2002, 232, 173-230. 
9. G. Wu, R. F. Barth, W. Yang, R. J. Lee, W. Tjarks, M. V. Backer and J. M. Backer, Anti-
Cancer Agents Med. Chem. , 2006, 6, 167-184. 
10. E. L. Crossley, E. J. Ziolkowski, J. A. Coderre and L. M. Rendina, Mini-Reviews Med. 
Chem., 2007, 7, 303-313. 
11. S. Aime, A. Barge, A. Crivello, A. Deagostino, R. Gobetto, C. Nervi, C. Prandi, A. Toppino 
and P. Venturello, Org. Biomol. Chem., 2008, 6, 4460-4466. 
12. A. Toppino, M. E. Bova, S. G. Crich, D. Alberti, E. Diana, A. Barge, S. Aime, P. Venturello 
and A. Deagostino, Chemistry, 2013, 19, 720-727. 
13. P. J. Kueffer, C. A. Maitz, A. A. Khan, S. A. Schuster, N. I. Shlyakhtina, S. S. Jalisatgi, J. 
D. Brockman, D. W. Nigg and M. F. Hawthorne, Proc. Natl. Acad. Sci. USA, 2013, 110, 
6512-6517. 
14. H. Nakamura, in Methods Enzym., ed. N. Duzgunes, 2009, pp. 179-208. 
15. S. Altieri, M. Balzi, S. Bortolussi, P. Bruschi, L. Ciani, A. M. Clerici, P. Faraoni, C. Ferrari, 
M. A. Gadan, L. Panza, D. Pietrangeli, G. Ricciardi and S. Ristori, J. Med. Chem., 2009, 52, 
7829-7835. 
16. V. P. Torchilin, Adv. Drug Deliv. Rev., 2008, 60, 548-558. 
17. A. P. Pathak, D. Artemov, B. D. Ward, D. G. Jackson, M. Meeman and Z. M. Bhujwalla, 
Cancer Res., 2005, 65, 1425-1432. 
18. M. R. Dreher, W. G. Liu, C. R. Michelich, M. W. Dewhirst, F. Yuan and A. Chilkoti, J Natl 
Cancer Inst 2006, 98, 335-344. 
19. H. Koganei, M. Ueno, S. Tachikawa, L. Tasaki, H. S. Ban, M. Suzuki, K. Shiraishi, K. 
Kawano, M. Yokoyama, Y. Maitani, K. Ono and H. Nakamura, Bioconjugate Chem., 2013, 
24, 124-132. 
20. H. Nakamura, Future Med. Chem., 2013, 5, 715-730. 
21. M. Bialek-Pietras, A. B. Olejniczak, S. Tachikawa, H. Nakamura and Z. J. Lesnikowski, 
Bioorg. Med. Chem., 2013, 21, 1136-1142. 
22. G. L. Pan, S. Oie and D. R. Lu, Pharm. Res., 2004, 21, 1257-1262. 
23. Z. J. Kaminski, Synthesis, 1987, 917-920. 
24. J. Schimmel, M. I. P. Eleuterio, G. Ritter and R. R. Schmidt, Eur. J. Org. Chem, 2006, 
1701-1721. 
25. A. Bajaj, P. Kondaiah and S. Bhattacharya, Bioconjugate Chem., 2008, 19, 1640-1651. 
26. E. I. Sega and P. S. Low, Canc. Metast. Rev., 2008, 27, 655-664. 
27. W. Xia and P. S. Low, J. Med. Chem., 2010, 53, 6811-6824. 
27 
 
28. Y. J. Lu and P. S. Low, Adv. Drug Deliv. Rev., 2002, 64, 342-352. 
29. B. A. Kamen and A. K. Smith, Adv. Drug Deliv. Rev., 2004, 56, 1085-1097. 
30. C. M. Paulos, J. A. Reddy, C. P. Leamon, M. J. Turk and P. S. Low, Mol. Pharm., 2004, 66, 
1406-1414. 
31. L. Tei, A. Barge, S. G. Crich, R. Pagliarin, V. Negri, D. Ramella, G. Cravotto and S. Aime, 
Chemistry, 2010, 16, 8080-8087. 
32. C. Grange, S. Geninatti-Crich, G. Esposito, D. Alberti, L. Tei, B. Bussolati, S. Aime and G. 
Camussi, Cancer Res., 2010, 70, 2180-2190. 
33. N. Kamaly, T. Kalber, M. Thanou, J. D. Bell and A. D. Miller, Bioconjugate Chem., 2009, 
20, 648-655. 
34. F. Olson, C. A. Hunt, F. C. Szoka, W. J. Vail and D. Papahadjopoulos, Biochim. Biophys. 
Acta, 1979, 557, 9-23. 
35. N. Protti, S. Bortolussi, M. I. M. Prata, P. Bruschi, S. Altieri and D. W. Nigg, Trans. Amer. 
Nucl. Soc., 2012, 107, 1269-1272. 
 
 
Scheme 1 C-(2-Benzyloxyethyl)-C’-[cholesten-5-en-3-yloxy-(3-propionacetoamidomethyl)]-o-
carborane (4). Reaction conditions and yields: a) MsCl, Et3N, Et2O, 0 °C → r.t (> 99%); b) 
HO(CH2)3OH, dioxane, 120 °C (27%); c) 3M CrO3 in H2SO4, acetone, r. t. (80%); d) 
Dicyclohexylcarbodiimide, CH2Cl2, rt (79%) or N-hydroxysuccinimide, 
diclohexylcarbodiimide, CH2Cl2, rt (64%); e). 
28 
 
 
Scheme 2 Synthesis of C-[DOTAMA-C6-)-carbamoylmethyl]-C’-[cholesten-5-en-3-yloxy-(3-
propionacetoamidomethyl)-o-carborane (9). Reaction conditions and yields: a) H2, Pd/C, 
EtOH, CH2Cl2, rt (92%); b) 3M CrO3 in H2SO4, acetone, r. t. (80%); c) N-
hydroxysuccinimide, Dicyclohexylcarbodiimide, i-PrEt2N, CH2Cl2, rt (42%); d) CF3COOH, 
CH2Cl2, r. t., (95%). 
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Scheme 3 Synthesis of Gd(III)-C-[N-(DOTAMA-C6)carbamoylmethyl]-C’-2-[1,3-
bis(hexadecyloxy)propan-2-yloxy]acetoamidomethyl-o-caborane complex (10, Gd-B-
AC01). a) GdCl3, H2O/MeOH 
 
 
 
 
